Bone Metastases

Gender Neutral
Type Module
Testing Phase validated

Project summary

The EORTC QLQ-BM22 is a 22-item questionnaire developed to assess health-related quality of life (HRQoL) in patients with bone metastases. It is designed to complement the EORTC QLQ-C30 and comprises four domains: painful sites, pain characteristics, functional interference, and psychosocial aspects.
The QLQ-BM22 has completed all four phases of EORTC module development and is fully validated. International Phase 4 field testing involving 400 patients across seven countries confirmed its reliability, validity, cross-cultural applicability, and responsiveness. The validation findings were published in Cancer in 2012 (Chow et al., doi:10.1002/cncr.26410).
We are also undertaking an update of the QLQ-BM22 to better capture HRQoL issues relevant to contemporary treatments and the evolving needs of patients with bone metastases.
We have recently completed Phases 1 and 2 of the update, resulting in a provisional 45-item module (QLQ-BM45), comprising the original 22 items and 23 additional items. The Phase 1–2 report is being finalised for EORTC QLG approval (pending final review of a requested minor revision), and we plan to proceed to Phase 3 pre-testing, followed by Phase 4 international validation.

Translations

Go to Top